- Trial Phase
- Filed/NDA under review (China) for PNH; Phase 3 ongoing (China) for IgAN; Phase 2 for Lupus Nephritis
- Time to Market
- China PNH approval possible within 6–12 months; ex-China (US/EU) approval likely 3–5 years away pending bridging studies.
- Why 6/10
- The next hard catalyst is the China NMPA decision on NXP100's two Marketing Authorization Applications (MAAs) for PNH, submitted ~March 2026, with decisions possible within 6–12 months. NXP100 is a major value driver for NVCT (which also has NXP200, NXP800, NXP900 programs), and the stock has already surged ~180% in the past month on the Haisco licensing deal and financing, so a binary approval catalyst is partially pre-loaded.
Watch for China NMPA decisions on the two PNH MAAs over the next 6–12 months — approval would validate the asset and support ex-China regulatory filings. However, the stock is technically overbought (RSI 91.3) and the recently priced $100M offering at $20/share (a ~30% discount to the prior close) creates near-term dilution overhang. The ex-China clinical pathway (bridging studies for FDA/EMA) is years away from potential revenue.
Price Chart
Executive Summary
NXP100 (HSK39297) is a once-daily oral complement Factor B inhibitor licensed by Nuvectis Pharma (NASDAQ: NVCT) from China's Haisco Pharmaceutical for ex-China rights in a deal worth up to $1.42B. Two China NMPA marketing applications are under review for PNH, a Phase 3 IgAN trial is ongoing, and Phase 2 LN data is accumulating. The drug competes directly with Novartis's already-approved iptacopan (Fabhalta) in the same target and indications. NVCT raised $100M in a dilutive June 2026 offering to fund development, and the stock has run sharply (+180% in one month). The China PNH approval decision is the nearest binary catalyst, but ex-China commercialization is years out and requires bridging studies.
How It Works
NXP100 is a once-daily pill that blocks the complement system's alternative pathway (specifically Factor B), which is part of the immune system's inflammatory cascade. In diseases like PNH and IgAN, this pathway is overactive and causes red blood cell destruction or kidney damage. By inhibiting Factor B, NXP100 aims to stop the damaging inflammation while preserving other immune functions.
Trial Status
Two MAAs are under NMPA review in China for PNH (treatment-naïve and C5-inhibitor-failure populations). A Phase 3 trial in IgAN is ongoing in China following positive Phase 2 data that showed a 45.3% proteinuria reduction vs placebo at Week 12, increasing to 57.7% at Week 24, plus favorable eGFR preservation. A Phase 2 trial in Lupus Nephritis is also underway. Ex-China, Nuvectis plans to initiate FDA/EMA bridging studies to enable Western registration.
The Two-Sided Case
Upcoming Catalysts
- China NMPA decisions on two PNH MAAs (expected H1 2027, possibly sooner if granted priority review)
- Phase 3 IgAN trial topline data (China)
- Initiation of FDA/EMA bridging studies for ex-China development
- Phase 1b/2 Lupus Nephritis data updates
- NXP200 and NXP900 oncology program readouts
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Nuvectis Pharma, Inc. 424B5 NVCT ·Originating report